Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 15Recruiting 10Active not recruiting 4Unknown 3No longer available 3Withdrawn 2Terminated 2Available 2Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 26Sarcoma 10Other hematologic neoplasm 5Genitourinary 5Lymphoid 4Plasma cell 3Myeloid 3Gynecologic 3Gastrointestinal 3Dermatologic 3Breast 3Endocrine 2Other solid neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 7Pheochromocytoma 6Thyroid Carcinoma, Anaplastic 5Pituitary Neoplasms 5Paraganglioma 5Insulinoma 5Somatostatinoma 4Vipoma 3Serotonin Syndrome 3Lung Neoplasms 3Glucagonoma 3Gastro-enteropancreatic neuroendocrine tumor 3Gastrinoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Carcinoma, Medullary 3Carcinoma, Islet Cell 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Unknown Primary 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Growth Hormone-Secreting Pituitary Adenoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

Tretinoin 1Isotretinoin 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neuroblastoma × Endocrine × Clear all
NCT06233903 2025-01-21

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 2 Withdrawn
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn
CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡